185 completed, 46 unknown, 41 recruiting, 38 active not recruiting. 365 Phase 3, 56 Phase 2.
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma Chidamide, Control Group - T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 3 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 132 | 2026-08-15 | 2026-08-19 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL BLB101 for Injection, Blinatumomab for Injection - Precursor B-cell Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 212 | 2026-08-09 | 2026-07-23 |
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | Nurix Therapeutics, Inc. | 620 | 2026-08-03 | 2026-08-31 |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) TQB3909 Tablets, Bendamustine Injection, Rituximab injection - Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 128 | 2026-08-01 | 2026-08-11 |
| A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma Gamunex-C, 10% Injectable Solution - Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Phase 3 | Recruiting | Grifols Biologicals, LLC | 49 | 2026-05-11 | 2026-10-01 |
| Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) Surovatamig - Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV | Phase 3 | Recruiting | AstraZeneca | 420 | 2026-05-05 | 2026-10-06 |
| Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL Zanubrutinib, Sonrotoclax, Computed Tomography - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 466 | 2026-04-30 | 2026-11-03 |
| ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Rocbrutinib, Pirtobrutinib - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 3 | Recruiting | Newave Pharmaceutical Inc | 306 | 2026-04-23 | 2026-11-10 |
| A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia Sonrotoclax, Zanubrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | BeOne Medicines | 500 | 2026-01-22 | 2026-09-28 |
| Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant | Phase 2 / Phase 3 | Recruiting | Bambino Gesù Hospital and Research Institute | 1000 | 2026-01-07 | 2026-10-20 |
| Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL targeted drug - Acute Lymphoblastic Leukemia | Phase 3 | Recruiting | Nanfang Hospital, Southern Medical University | 154 | 2025-10-01 | 2025-10-02 |
| A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) DZD8586, Bendamustine, Idelalisib - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 3 | Recruiting | Dizal Pharmaceuticals | 250 | 2025-09-08 | 2026-06-03 |
| A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Tacabrutideg, Pirtobrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | BeOne Medicines | 500 | 2025-09-04 | 2026-09-28 |
| Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies Cyclosporine A (CsA), Sirolimus, Ruxolitinib (JAKAVI®) - Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk | Phase 2 / Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 64 | 2025-09-03 | 2026-01-26 |
| A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Venetoclax, Azacitidine - Leukemia, B-Cell, Chronic, Leukemia | Phase 3 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 262 | 2025-09-01 | 2025-07-24 |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) Sonrotoclax, Obinutuzumab, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | BeOne Medicines | 630 | 2025-06-11 | 2026-10-23 |
| Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL Induction Therapy Regimen, Pre-Treatment Regimen, Post-CR Treatment - Acute Lymphoblastic Leukemia, Adult | Phase 2 / Phase 3 | Recruiting | Shanxi Bethune Hospital | 50 | 2025-06-01 | 2025-07-10 |
Showing 20 of 365. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (198) · Leukemia, Lymphocytic, Chronic, B-Cell (176) · Leukemia (83) · Lymphoma (67) · Lymphoma, Non-Hodgkin (67) · Leukemia, Myeloid, Acute (65) · Lymphoma, Follicular (57) · Burkitt Lymphoma (53) · Lymphoma, B-Cell, Marginal Zone (48) · Lymphoma, Large B-Cell, Diffuse (48) · Lymphoma, Mantle-Cell (48) · Myelodysplastic Syndromes (42) · Hodgkin Disease (41) · Multiple Myeloma (40) · Lymphoma, Large-Cell, Immunoblastic (39)
Hemic and Lymphatic Diseases (365) · Immune System Diseases (365) · Lymphatic Diseases (365) · Neoplasms by Histologic Type (365) · Immunoproliferative Disorders (364) · Hematologic Diseases (361) · Lymphoproliferative Disorders (358) · Neoplasms (343) · Leukemia (282) · Pathological Conditions, Signs and Symptoms (213) · Pathologic Processes (212) · Disease Attributes (208) · Chronic Disease (201) · Leukemia, B-Cell (171)
Cyclophosphamide (92) · Methotrexate (66) · Vincristine (59) · Rituximab (55) · Cytarabine (54) · Dexamethasone (50) · Doxorubicin (43) · Mercaptopurine (43) · pegaspargase (40) · Daunorubicin (36) · Prednisone (36) · Asparaginase (33) · Etoposide (33) · Radiotherapy (31) · venetoclax (29)
Children's Oncology Group (21) · German CLL Study Group (12) · National Cancer Institute (NCI) (12) · Gilead Sciences (10) · Hoffmann-La Roche (10) · Novartis Pharmaceuticals (9) · European Organisation for Research and Treatment of Cancer - EORTC (8) · St. Jude Children's Research Hospital (8) · Fred Hutchinson Cancer Center (7) · Nanfang Hospital, Southern Medical University (7) · BeOne Medicines (6) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (6) · Institute of Hematology & Blood Diseases Hospital, China (6) · AbbVie (5) · Alliance for Clinical Trials in Oncology (5)
United States (199) · Canada (91) · France (88) · Australia (86) · Germany (86) · Italy (83) · United Kingdom (80) · Spain (73) · Belgium (64) · Poland (63) · Czechia (56) · China (55) · Sweden (52) · Austria (50) · Israel (50)
Michael Hallek, MD (7) · Xiaofan Zhu, MD (4) · Anne L Angiolillo (2) · Barbara Eichhorst, MD (2) · Barbara Eichhorst, MD, Prof. (2)
PMID 33242441, PMID 38620092, PMID 39121442, PMID 40266025, PMID 28751558, PMID 31196847, PMID 33131249, PMID 34865212, PMID 37341189, PMID 37890117, PMID 38446568, PMID 41671463, PMID 15812540, PMID 21195303, PMID 24797299, PMID 24916506, PMID 24970932, PMID 25103870, PMID 25753432, PMID 26590194, PMID 29255066, PMID 29284596, PMID 29880603, PMID 31188727, PMID 31612640, PMID 32499241, PMID 32599655, PMID 32735048, PMID 35014928, PMID 35377947, PMID 35622074, PMID 35829925, PMID 36603187, PMID 36617990, PMID 38502198, PMID 38598745, PMID 39316653, PMID 39563886, PMID 40315406, PMID 40396505, PMID 40908865, PMID 40944848, PMID 41592282, PMID 41749915, PMID 42085640, PMID 10499612, PMID 10627444, PMID 11426549, PMID 11675328, PMID 12111109
U10CA098543 (13), U10CA180886 (9), 2023 (8), 2025 (6), 2009 (5), 2014 (5), 2015 (4), 2017 (4), U10CA021115 (4), U10CA095861 (4), 2016 (3), 2019 (3), U10CA180820 (3), UG1CA189955 (3), 2005 (2)